Standard of care and promising new agents for triple negative metastatic breast cancer.

ABSTRACT: Triple negative breast cancer (TNBC) is a cluster of heterogeneous diseases, all of them sharing the lack of expression of estrogen and progesterone receptors and HER2 protein. They are characterized by different biological, molecular and clinical features, including a poor prognosis despite the increased sensitivity to the current cytotoxic therapies. Several studies have identified important molecular features which enable further subdivision of this type of tumor. We are drawing from genomics, transcription and translation analysis at different levels, to improve our knowledge of the molecular alterations along the pathways which are activated during carcinogenesis and tumor progression. How this information should be used for the rational selection of therapy is an ongoing challenge an

SUBMITTER: Mancini P 

PROVIDER: S-EPMC4276962 | biostudies-literature | 2014 Oct

REPOSITORIES: biostudies-literature